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Abstract
ERRa is an orphan nuclear receptor emerging as a novel biomarker of breast cancer. Over-expression of ERRa in breast
tumor is considered as a prognostic factor of poor clinical outcome. The mechanisms underlying the dysexpression of this
nuclear receptor, however, are poorly understood. MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional
level and play important roles in tumor initiation and progression. In the present study, we have identified that the
expression of ERRa is regulated by miR-137, a potential tumor suppressor microRNA. The bioinformatics search revealed
two putative and highly conserved target-sites for miR-137 located within the ERRa 39UTR at nt 480–486 and nt 596–602
respectively. Luciferase-reporter assay demonstrated that the two predicted target sites were authentically functional. They
mediated the repression of reporter gene expression induced by miR-137 in an additive manner. Moreover, ectopic
expression of miR-137 down-regulated ERRa expression at both protein level and mRNA level, and the miR-137 induced
ERRa-knockdown contributed to the impaired proliferative and migratory capacity of breast cancer cells. Furthermore,
transfection with miR-137mimics suppressed at least two downstream target genes of ERRa–CCNE1 and WNT11, which are
important effectors of ERRa implicated in tumor proliferation and migration. Taken together, our results establish a role of
miR-137 in negatively regulating ERRa expression and breast cancer cell proliferation and migration. They suggest that
manipulating the expression level of ERRa by microRNAs has the potential to influence breast cancer progression.
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Introduction
Human breast cancer is a malignant tumor with high level of
heterogeneity. Intricate signaling network is the molecular
foundation of the malignant progression and heterogeneity
formation of breast tumor [1]. Studies in the past decades have
revealed several classic signaling molecules involved in breast
tumorigenesis, such as estrogen receptor alpha (ERa) [2], pro-
gesterone receptor (PR) [3] and human epidermal growth factor
receptor-2 (HER2) [4], all of which have been identified as
biomarkers for molecular classification of breast cancer and targets
of individual therapy of the disease [5,6,7].
Nowadays, nuclear receptor estrogen-related receptor a (ERRa)
is considered to be another important component of breast cancer
signaling network and is emerging as a novel biomarker of the
disease [8]. ERRa was originally cloned using the DNA-binding
domain (DBD) of ERa as a probe to screen the human cDNA
library [9]. Despite its significant homology with ERa, ERRa does
not respond to estrogen or estrogen-like molecules. Actually, no
endogenous ligand for ERRa has been identified so far. Moreover,
crystallographic studies have suggested that the ligand binding
domain (LBD) of ERRa can recruit co-regulators in a ligand-
independent manner [10,11]. In another word, ERRa is
a constitutively active orphan nuclear receptor. The primary
physiological role of ERRa can be viewed as a regulator of energy
metabolism, which is required for cell adaption to various stresses
and energy needs [12]. Recent studies have been portraying
a picture about the implication of ERRa in breast cancer initiation
and progression. First, breast cancer tissues express a higher level
of ERRa compared to adjacent benign tissues, which is
significantly correlated with an increased risk of recurrence and
adverse clinical outcome [8,13,14]. Second, ERRa interferes with
the estrogen signaling pathway both through participating in the
local mammary steroidogenesis [15,16] and through co-regulating
a group of genes with ERa [17,18]. Third, there is a reciprocal
relationship between ERRa and HER2 signaling pathway. The
transcriptional activity of ERRa can be enhanced by the EGF-
HER2 signaling pathway [19,20]. In turn, activated ERRa can
enhance the expression of the HER2 gene ERBB2 [21]. The
positive regulatory loop between ERRa and EGF-HER2 pathway
is considered to promote the conversion of ERa-positive luminal
breast tumor into a more aggressive HER2-positive type [21].
Finally, transcriptome analysis on a genome-wide scale has shown
that ERRa can independently regulate the expression of a large
number of genes that mediate a range of biological processes, such
as metabolism, cell proliferation, cell cycle, apoptosis, metastasis
and transcription [17]. By intersecting the ERRa target genes in
breast cancer cells with the gene expression profiles of several
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contribute to the heterogeneity of the disease [17].
In summary, ERRa is a signaling molecule widely expressed in
different subtypes of breast tumor, which independently and/or
coordinately modulates the tumor progression. Therefore, finding
an effective approach to manipulate the activity or the expression
of ERRa has profound significance for the therapy of breast
cancer. Currently, several synthetic compounds have been
identified as inverse agonists of ERRa to modulate its transcrip-
tional activity [22,23,24], however, the regulatory mechanisms of
its gene expression are poorly understood. It was reported that
ERRa can regulate the expression of itself through binding to the
multiple-hormone response element (MHRE) located within the
promoter region of the ERRa gene [25]. The positive auto-
regulatory loop is a guarantee for cell to immediately adapt to
energy needs for some physiological stresses. Besides ERRa, the
ERRc and ERa were discovered to regulate the ERRa gene
transcription through the MHRE [26,27]. However, besides at
transcriptional level, are there any regulatory mechanisms at
additional levels? Furthermore, what is the mechanism underlying
the up-regulation of the basal level of the ERRa protein in breast
tumorigenesis? These issues remain to be elucidated.
MicroRNAs (miRNA) are a class of endogenous, small, non-
coding RNAs. Mature miRNAs (generally 18–25 bp nucleotides in
length) act as regulators of gene expression at the post-
transcriptional level via sequence-specific interaction with the
target mRNA [28,29]. It is estimated that the expression of up to
60% of all protein-coding genes are under the control of miRNAs
[30]. Therefore, miRNAs are involved in a range of cellular
processes related to carcinogenesis. It has been shown that
miRNAs can act as oncogenes or tumor suppressor genes, and
aberrant expression of miRNAs occurs in various tumors [31,32].
In breast cancer, miRNAs signatures are correlated with the
biopathologic features of different breast tumor subtypes [33]. To
date, numerous miRNAs, such as miR-21, miR-125, miR-200,
miR-221/222 and so on, were reported to be aberrantly expressed
in breast cancer [34]. The studies aimed at exploring their
functions in breast cancer revealed that a lot of signaling molecules
including ERa and HER2, were targets of miRNAs [34,35].
Therefore, uncovering the relationship between miRNAs and key
human breast cancer biomarker gene will provide us an additional
perspective to recognize the mechanism underlying breast cancer
initiation and progression.
The present study is aimed at exploring the potential of
regulating the ERRa expression by microRNAs. Our results show
that miR-137, a potential tumor suppressor microRNA, can
negatively modulate the expression of ERRa and suppress the
growth and migration of breast cancer cells partly through two
immediate downstream effectors of ERRa-cell cycle protein
cyclinE1 and WNT11.
Results
The 39UTR of ERRa mRNA Contains Two Functional
Target Sites for miR-137
To identify the miRNAs that target ERRa, we performed
a bioinformatics search employing three well-known prediction
algorithms (TargetScan [36], PicTar [37] and miRanda [38]).
MiR-137 was predicted as a potential microRNA that targets the
ERRa gene (ESRRA NM_004451) by these three algorithms.
Moreover, two putative target sites (AGCAAUA) for the miR-137
seed sequence (UAUUGCU)were predicted to be located within
the ESRRA 39UTR at nt 480–486 (named target site A ) and nt
596–602 (named target site B) respectively (Fig. 1A). More
importantly, both of them are highly conserved across different
species (Fig. 1B).
To investigate the interaction between miR-137 and its
predicted target sites within ESRRA 39UTR and to evaluate the
relative contribution of each miR-137 binding site to the
interaction, we generated a series of dual luciferase reporter
plasmids (Fig. 1C and 1D). These included plasmids with
perfect miR-137 target sequence (miR-137 target), mismatched
miR-137 target site (gmiR-137 target), full-length wild-type
ESRRA 39UTR (WT 39UTR), or mutated ESRRA 39UTR. At
first, we tried to determine whether the synthetic miR-137
mimics could recognize its target site in our reporter assay
system. To this end, we employed the reporter plasmid–‘‘miR-
137 target’’ as the systemic positive control and the ‘‘gmiR-137
target’’ as the negative control. As shown in Figure 1C, in
HepG2 cells (a cell line that expresses relatively low level of
endogenous ERRa (Fig. S1)), miR-137 mimics reduced the
luciferase activity of plasmid ‘‘miR-137 target’’ by 80%. In
contrast, we did not observe that miR-137 reduced the
expression of empty plasmid or plasmid with mismatched
miR-137 target (gmiR-137 target).
We next tested the interaction between miR-137 and the 39-
UTR of ESRRA. Our data showed that compared with NC
oligos, miR-137 mimics also dramatically decreased the luciferase
activity of reporter plasmid with the intact ESRRA 39UTR.
Furthermore, no matter whether target site A or target site B was
deleted (mutant A and mutant B) the decrease of luciferase activity
was compromised to a certain extent. As shown in Figure 1D,
miR-137 could decrease the luciferase activity of the reporter
plasmid with WT 39UTR to 43% of NC oligos treated group. If
site B was deleted, the decreased activity of the reporter plasmid
was restored to about 55%, whereas once site A was deleted, the
luciferase activity was restored to 78%. Not surprisingly, once both
miR-137 target sites were lost (mutant C), the activity of the
reporter gene was no longer affected by miR-137 mimics at all.
Taken together, these data indicate that ESRRA 39UTR is
a specific direct target of miR-137. The two predicted target sites
possess unequal ability to interact with miR-137 (target site A is the
major functional miR-137 binding site) but both of them are
functional and can mediate the repression of reporter gene
expression in an additive manner.
Breast Cancer Cells Lose miR-137 and Express High Level
of ERRa
To establish functional association between ERRa and miR-
137, we measured miR-137 and ERRa expression in normal
breast epithelial cell line MCF-10A and five different breast cancer
cell lines. The data showed that compared with MCF-10A, all
breast cancer cell lines over-expressed ERRa (Fig. 2A) and lost the
endogenous miR-137 (Fig. 2B). Furthermore, the results from
available breast cancer cell lines showed that in the cell lines with
relatively higher endogenous miR-137 expression (such as MDA-
MB-231), a lower amount of ERRa protein was detected, whereas
cell lines with lower miR-137 expression (for example SK-BR-3,
BT-474 and MCF-7) showed higher amounts of the ERRa protein
(Fig. 2). Although this inverse correlation between miR-137 and
ERRa level was not statistically significant, it provides a possibility
that the loss of miR-137 may be involved in the dysexpression of
ERRa in breast tumorigenesis. Of course, as the number of
available breast cancer cell lines is limited and these cultured cell
lines can not stand for all subtypes of breast tumor, a more
systemic study using clinical breast cancer samples is required to
help us define the correlation between the endogenous expression
level of ERRa and that of miR-137.
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Given that the reporter assay showed that the 39UTR of
ESRRA contained functional miR-137 target sites, we sought to
determine the effect of miR-137 mimics treatment on the
regulation of the endogenous ERRa expression. As shown in
Figure 3A, SK-BR-3 transfected with miR-137 mimics showed
a dramatic decrease in ERRa expression at both protein level
and mRNA level, compared with that of the control group.
This is similar to that caused by si-ERRa transfection (Fig. 3A).
Furthermore, if the SK-BR-3 cells were co-tranfected with miR-
137 mimics and equal amount of specific miR-137 inhibitors,
the down-regulation of ERRa expression at both protein level
and mRNA level could be significantly reversed (Fig. 3B). These
results demonstrate that the expression level of the endogenous
ERRa can be manipulated by enforced transfection of miR-137.
Herein, we should mention that although the interaction
between microRNA and its target gene could induce target
mRNA degradation, we can not ignore that ERRa can regulate
the transcription of itself. Therefore, the down-regulation of
ERRa expression at mRNA level observed by us may also be
a post-effect of the decrease of the ERRa protein induced by
miR-137.
Ectopic Expression of miR-137 Inhibits Cell Proliferation
and Induces Cell Cycle Arrest in Breast Cancer Cells
Recent studies employing siRNAs and synthetic antagonists
have demonstrated that ERRa is required for the growth of
multiple breast cancer cells in vitro or when propagated as
xenografts [18,39,40]. Furthermore, results from functional
genomic studies also showed that ERRa can directly regulate
the expression of some genes associated with proliferative
phenotype [17,18]. Together, these data suggest that ERRa may
be a regulator of breast tumor proliferation. Given that our data
showed that miR-137 down-regulated the expression of ERRa,w e
Figure 1. Identification of two highly conserved miR-137 target sites within the ESRRA 39UTR. A. Schematic representation of the ERRa
(ESRRA) mRNA with two putative sites (A and B) targeted by miR-137. B. Sequence alignment of predicted miR-137 target sites located within ESRRA
39UTR showing high conservation among different species. The sequence of miR-137 target sites in ESRRA 39UTR is shown in underlined. C. Luciferase
reporter assay to verify activity of miR-137 upon the consensus miR-137 target site. HepG2 cells were transfected with Empty reporter plasmids,
luciferase constructs containing perfect match miR-137 target site (miR-137 target) or mismatch miR-137 target site (gmiR-137 target) and either
miR-137 mimcs or NC oligos. Luciferase activity was determined 24 hr after transfection. Relative luciferase expression (firefly normalized to Renilla)
values are the ratio of miR-137-treated reporter vector compared with the same NC oligos-treated reporter vector. Data are representative of at least
three independent experiments. Error bars: SD. ***: P,0.0001. D. Luciferase reporter assay to evaluate the interaction between miR-137 and 39-UTR of
ESRRA. HepG2 cells were transfected with luciferase constructs containing wild-type (WT 39UTR) or deletion mutated ESRRA 39UTR (mutant A, mutant
B and mutant C) and either miR-137 mimcs or NC oligos. Luciferase activity was determined 24 hr after transfection. Relative luciferase expression
(firefly normalized to Renilla) values are the ratio of miR-137-treated reporter vector compared with the same NC oligos-treated reporter vector. Data
are representative of three independent experiments. Error bars: SD. *: p,0.05, ***: P,0.0001.
doi:10.1371/journal.pone.0039102.g001
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mise the growth of breast cancer cells.
Meanwhile, we also observed some papers declaring that
modifying the expression of ERRa with si- or shRNA dose not
impact cell proliferation in vitro [41,42]. Thus, in order to
evaluate the effect of small RNAs –mediated knockdown of ERRa
on the cell proliferation, we transfected four different types of
breast caner cell line with miR-137 mimics, si-ERRa and negative
control oligos in parallel. The efficiency of miR-137 and si-ERRa
in reducing the expression of ERRa in these cells was confirmed
by western blot assay (Fig. S2). As shown in Figure 4, the silencing
of ERRa significantly decreased the growth rate of breast cancer
cell line MCF-7 (ERa-positive/HER2-negative), BT-474 (ERa-
positive/HER2-positive) and SK-BR-3 (ERa-negative/HER2-
positive), whereas, hardly influenced that of ERa-negative/
HER2-negative breast cancer cell line MDA-MB-231. This
phenomenon could be explained by the hypothesis that ERRa is
an orphan nuclear receptor exhibiting tissue/cell-specific bi-
ological function.
Since the SK-BR-3 cell line is generally considered as a cellular
model of breast cancer exhibiting high ERRa activity and is
sensitive to growth inhibition by ERRa depletion or inactivation
[39], we further investigated the detailed mechanisms underlying
the inhibition of cell proliferation mediated by miR-137 in this cell
line. Analysis of cell cycle phase distribution by cytometry showed
that compared with negative control group, the cell cycle
progression of SK-BR-3 cells transfected with miR-137 mimics
were arrested at G1 phase with a significant decrease in S and G2
phase. While the miR-137 mimics were ‘‘neutralized’’ by the co-
transfected miR-137 inhibitors, the percentage of G1 phase
decreased, and the other phases increased accordingly, suggesting
that cell cycle G1 phase arrest was partly reversed (Fig. 5A).
Furthermore, the absence of a sub-G1 cell population was detected
by flow cytometry, suggesting that the transfection of miR-137
does not lead to cell apoptosis (Fig. 5A). In addition, we also
observed the effect of miR-137 on cell cycle progression by BrdU
incorporation assay. As shown in Figure 5B, after transfection of
miR-137, the number of cells in cell cycle S phase decreased
significantly. Taken together, these data indicate that the ectopic
expression of miR-137 can trigger cell proliferation inhibition
through arresting cell cycle at G1 phase.
Figure 2. MiR-137 and ERRa levels in normal breast epithelial and breast cancer cell lines. A. Western-blot analysis for ERRa protein level
in normal breast epithelial cell line (MCF-10A) and five breast cancer cell lines. b-actin was used as the loading control. B. qRT-PCR analysis for miR-137
expression level. The miR-137 expression was normalized to RNU6B-small nuclear RNA. Data are representative of three independent experiments
performed in triplicate. Error bars: SD.
doi:10.1371/journal.pone.0039102.g002
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Regulating the Expression of ERRa Downstream Target
Gene-cell Cycle Protein CyclinE1 (CCNE1)
Given that our study suggested that depletion of ERRa by miR-
137 could impair the cell cycle progression, we wondered which
ERRa-regulated pathways might contribute to this effect. Accord-
ing to the result of genome-wide identification of direct target
genes of ERRa in breast cancer cell lines, cell cycle protein
cyclinE1 (CCNE1), which regulates the progression of cell cycle
from G1 to S phase, could be a direct target gene of ERRa [17].
As an initial step in our analysis, we demonstrated that in SK-BR-
3 cells, the expression of CCNE1 was indeed under the control of
ERRa. As shown in Figure 6A, treatment with the specific inverse
agonist XCT-790 resulted in the dose-dependent inhibition of
CCNE1 expression at both transcriptional and protein levels.
Furthermore, the knock-down of ERRa by si-ERRa exhibited
similar effect on the CCNE1 expression (Fig. 6B). We then
evaluated the expression of CCNE1 in SK-BR-3 cells following the
treatment of miR-137 mimics. Not surprisingly, a markedly
decrease of CCNE1 expression at both mRNA level and protein
level was observed in the SK-BR-3 cells transfected with miR-137
mimics. Moreover, this effect was reversed by the existence of
specific miR-137 inhibitors (Fig. 6C), suggesting that miR-137
mimics has the effect on the regulation of CCNE1 expression.
In order to demonstrate that miR-137 acts on the regulation of
CCNE1 expression and cell cycle progression through ERRa,w e
tested whether exogenously expressed ERRa (without 39-UTR)
could restore the reduced CCNE1 expression and impaired
proliferative phenotype in SK-BR-3. In cells treated with NC
oligos, overexpression of ERRa failed to significantly increase the
expression of CCNE1 or promote the cell proliferation (Fig. 7),
probably due to a sufficiently high endogenous level of ERRa
already existing in SK-BR-3 cells. However, ectopic transfection
with plasmid encoding ERRa without 39-UTR robustly reversed
the decreased expression of CCNE1 induced by miR-137 at both
transcriptional and protein levels (Fig. 7A), and partly restored the
arrested proliferation (Fig. 7B and 7C). Together, all of these data
indicate that miR-137 induces cell cycle G1 phase arrest and cell
proliferation suppression, at least in part, via the ERRa–cyclinE1
pathway.
MiR-137 Influences the Migratory Capacity of MDA-MB-
231 Partly through ERRa-WNT11 Signaling Pathway
In addition to its role in the regulation of cancer cell
proliferation, ERRa has been implicated in promoting cancer
cell migration [18,43]. MDA-MB-231 is a breast cancer cell line
with high migratory capacity. In our study, we did not observe the
significant inhibition of growth in MDA-MB-231 treated with
miR-137 mimics (Fig. 4) but we found that treatment of miR-137
led to dramatic decrease in migration/invasion of MDA-MB-231
(Fig. 8A), which is consistent with the previous study that
knockdown of ERRa by si-ERRa in MDA-MB-231 had no effect
on in vitro cell proliferation but reduced the migratory potential of
these cells [18].
Figure 3. Ectopic transfection of miR-137 regulates the endogenous ERRa expression level. A. Western blot analysis for ERRa protein level
and qRT-PCR analysis for ERRa mRNA level in SK-BR-3 cells 48 hr after transfection regent treatment (mock) or transfection with indicated RNA
oligonucleotides (50 nM). B. Western blot analysis for ERRa protein level and qRT-PCR analysis for ERRa mRNA level in SK-BR-3 cells 48 hr after
transfection regent treatment (mock) or cotransfection with equal amount of indicated RNA oligonucleotides. ERRa mRNA expression was normalized
to b-actin mRNA expression. The relative level of ERRa expression determined using the 2-
ggCT method. Data are representative of three
independent experiments performed in triplicate. Error bars: SD; *: p,0.05; ***: P,0.0001.
doi:10.1371/journal.pone.0039102.g003
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which miR-137 inhibits the migration of MDA-MB-231. Given
that WNT11 has been considered as a key mediator of the
promigratory activity of ERRa/b-cat complex in several cancer
cell lines including MDA-MB-231 [43], we tested the effect of
miR-137 on regulating the expression of WNT11. As shown in
Figure 8B, miR-137 exhibited high efficacy in reducing the
expression of endogenous ERRa and its target gene WNT11 at
both transcriptional and protein levels in MDA-MB-231. More
importantly, the reduced expression of WNT11 was partly
restored by the ectopic expression of ERRa without 39-UTR.
Furthermore, we also observed that the re-expression of ERRa
deleted from its 39-UTR significantly restored the migratory
capacity impaired by miR-137 mimics. Meanwhile, our data also
showed that the experimental treatment did not influence the
viability of treated cells (Fig. 8A). Together, these data suggest that
miR-137 decreases the migration/invasion of MDA-MB-231
partly through ERRa-WNT11 pathway.
Discussion
Increasing evidences in the past few years, especially the high
throughput functional genomic studies have demonstrated that
ERRa is an orphan nuclear receptor that plays important roles in
breast cancer progression and the heterogeneity of the disease
[44]. To further understand the contribution of ERRa to breast
cancer progression, it is essential to better define the detailed
regulatory mechanism of ERRa expression. However, the
mechanisms underlying the dysexpression of this nuclear receptor
in breast cancer remain to be investigated.
As microRNAs are very important regulators of gene expression
and so far there is no report about the regulation of ERRa by any
microRNA, we sough to determine whether the expression of
ERRa is under the control of microRNAs. Through biochemical
experiment we demonstrated that miR-137 significantly down-
regulated the expression of ERRa in breast cancer cells through
recognizing two highly-conserved miR-137 target sites located in
the 39-UTR of ERRa. MiR-137 is located on chromosome 1p22,
a region embedded in a CpG island. Therefore, this miRNA has
been found to be frequently silenced by methylation in several
cancers including colorectal cancer [45], gastric cancer [46], uveal
melanoma [47], oral cancer [48], glioblastoma multiforme [49]
and squamous cell carcinoma of the head and neck [50,51], and
potentially acts as a tumor suppressor microRNA in these tumors.
However, the expression level and downstream target genes of
miR-137 as well as its biological roles in breast cancer are still
unknown. In our study, we found that compared with that of
normal breast epithelial cell line (MCF-10A), the expression level
of miR-137 was also dramatically decreased in different breast
cancer cell lines. Furthermore, there seemed to be an inverse
association between the miR-137 level and the ERRa expression
in the breast cancer cell line we tested, which suggests that the
silencing of miR-137 in tumor cells, especially in breast cancer,
may be involved in the dysregulation of ERRa and contributed to
breast tumorigenesis.
Based on the finding that miR-137 regulates the expression of
ERRa, we further investigated the functional consequence of
this effect. In the past few years, a large number of studies
made efforts to elucidate the direct effect of ERRa in breast
tumor biology [42]. Although results from functional genomic
Figure 4. The effect of si-ERRa and miR-137–mediated knockdown of ERRa on the cell proliferation. Breast cancer cell lines (MCF-7, BT-
474, SK-BR-3 and MDA-MB-231) were transfected with 50 nM NC oligos, si-ERRa or miR-137 mimics or treated with transfection reagent alone (mock)
and seeded in 96-well plates. Plates were harvested at 1, 2, 3, 4, 5 days after seeding for CCK-8 assay.
doi:10.1371/journal.pone.0039102.g004
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associated with cell metabolism [17,18], whether and how its
role as metabolic regulator is involved in the pathophysiology of
cancer remains to be addressed. Moreover, some reports have
shown that, in tumor cells, ERRa exert other effects aside from
the activity of metabolic control, such as the direct regulation of
tumor proliferation and migration [39,43]. Therefore, we
focused our study on the effect of miR-137 on modulating
the proliferative and migratory capacity of breast cancer cell
lines. In our studies, we observed that the knock –down of
ERRa by either si-ERRa or miR-137 impaired the proliferation
of breast cancer cell lines we tested except that of MDA-MB-
231. For MDA-MB-231, silencing of ERRa had little impact on
the cell growth but dramatically inhibited its migratory capacity.
This kind of cell-specific consequence of loss of ERRa may
result from the cell-specific biological function of the nuclear
receptor. ERRa is an orphan nuclear receptor whose biological
effect dependents on the combination with various co-regulators,
which suggests that in different molecular environment, ERRa
may exert different functions. Given the complexity of
molecular environment of different breast cancer cell lines, we
took SK-BR-3 (a breast cancer cell line that is sensitive to
growth inhibition induced by depletion of ERRa) and MDA-
MB-231 (a breast cancer cell line with high migratory capacity)
as cell models respectively to further elucidate the mechanism
underlying the inhibitory effect of miR-137 on the proliferation
and migration of breast cancer cells. Of course, we also realized
that the functional effects of miR-137 treatment we observed
here were not solely the consequence of the change of the
ERRa level. Actually, besides ERRa, some other genes (such as
Cdc42 [52]) associated with cell proliferative and migratory
phenotypes are also the targets of miR-137. Therefore, we took
Figure 5. MiR-137 induces cell cycle G1 arrest in SK-BR-3 cells. A. Cell cycle analysis in SK-BR-3 cells transfected with indicated RNA
oligonucleotides for three days using propidium iodide staining and flow cytometry. The percentage of cells in each cell cycle phases was quantified.
Data are representative of three independent experiments performed in duplicate. Error bars: SD; *: p,0.05; **: P,0.01. B. BrdU incorporation assay
performed in SK-BR-3 cells transfected with indicated RNA oligonucleotides for three days. Data are representative of three independent experiments
performed in triplicate. Error bars: SD; **: P,0.01; ***: P,0.0001.
doi:10.1371/journal.pone.0039102.g005
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expression to evaluate the contribution of ERRa to these
effects. Our data suggest that down-regulation of ERRa
expression is at least one component of the mechanisms
underlying the tumor-suppressing effect of miR-137 in breast
cancer.
In the present study, we also tested the expression of some
tumorigenesis-related target genes of ERRa after miR-137
treatment. Among them, two identified ERRa direct down-stream
target genes: CCNE1 and WNT11 are of particular interest to us.
CyclinE1 is not only an important cell cycle regulator, but also an
independent prognostic marker of breast cancer [53,54]. The gene
CCNE1 was found to be amplified in about 12% of invasive breast
tumor patients [55]. Furthermore, the latest study showed that the
overexpression of CCNE1 in HER2 positive tumor can impair the
anti-HER2 therapy through resulting in resistance to trastuzumab
both in vitro and in vivo, whereas the mechanisms leading to
CCNE1 over-expression in these cells are unclear [56]. Our study
validated the existence of activated ERRa-CCNE1 signaling
pathway in HER2-positive breast cancer cell line–SK-BR-3,
which suggests that the dysexpression of ERRa may be one of
the factors contributing to the over-expression of CCNE1 in breast
tumor. As miR-137 interferes with the ERRa-CCNE1 axis, its role
and therapeutic value in breast cancer, especially in the HER2
positive breast cancer are worth further investigation. WNT11 has
been found upregulated in several cancers [57], and its expression
has been previously associated with increased cell migration [58].
Recent study demonstrated that WNT11 expression is directly co-
regulated by ERRa and b-catenin in several cancer cells, which is
considered as the key mechanism underlying the promigratory
activity of ERRa [43]. In the present study, we demonstrated that
miR-137 decreased the migration/invasion of MDA-MB-231
partly through ERRa-WNT11 pathway, providing an alternative
way to inhibit the migration of cancer cells with high migratory
capacity.
In addition, we also noticed that the ectopic expression of miR-
137 did not interfere with all of the ERRa signaling pathways.
Although miR-137 indeed changes the expression of some ERRa
Figure 6. The expression of ERRa downstream target gene CCNE1 is regulated by miR-137. A. Western blot analysis for ERRa and CylinE1
protein level and qRT-PCR analysis for CCNE1 mRNA level in SK-BR-3 cells 48 hr after DMSO or XCT-790 treatment. B. Western blot analysis for CylinE1
protein level and qRT-PCR analysis for CCNE1 mRNA level in SK-BR-3 cells 48 hr after transfection regent treatment (mock) or transfection with NC
oligos or si-ERRa. C. Western blot analysis for CylinE1 protein level and qRT-PCR analysis for CCNE1 mRNA level in SK-BR-3 48 hr after transfection
regent treatment (mock) or co-transfection with equal amount of indicated RNA oligonucleotides. CCNE1 mRNA expression was normalized to b-
actin mRNA expression. The relative level of CCNE1 mRNA was determined using the 2-
ggCT method. Data are representative of three independent
experiments performed in triplicate. Error bars: SD; *: p,0.05; **: P,0.01; ***: P,0.0001.
doi:10.1371/journal.pone.0039102.g006
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mentioned above, the expression of other identified classic ERRa
target genes including HER2 (ERBB2) (Fig. S3) and VEGF (data
not shown) seems not to be affected by miR-137. To our
knowledge, a reasonable explanation to this phenomenon may be
the complexity of the gene transcriptional regulation. Usually, the
transcription of a certain gene is under the control of multiple
transcriptional factors or cofactors, and the alteration of the
expression level is a result of the dynamic balance of each
component in this complex. Moreover, as it was mentioned above,
one certain microRNA can also target more than one molecule.
This means ERRa is not the only transcriptional factor targeted by
miR-137 in the same cell.
In conclusion, our studies establish a role of miR-137,
a microRNA having potential tumor suppressor activity, in
negatively regulating the expression of ERRa, a nuclear receptor
considered to facilitate the progression of breast cancer, and in
inhibiting the proliferative and migratory phenotype of some
breast cancer cells. These results expand our understanding of the
mechanism underlying the regulation of ERRa expression and
suggest that the aberrant expression of miR-137 may be involved
in breast cancer progression. The ectopic expression of miR-137
may serve as a useful tool in manipulating the expression level of
ERRa and exploring the function of ERRa in breast cancer.
Materials and Methods
RNA Oligonucleotides
Has-miR-137 mimics, has-miR-137 inhibitors, siRNA against
ERR a (sense: 59- AGAGGAGUAUGUUCUACUAAAGGCC-
39) negative control (NC) oligos (sense: 59-UUCUCCGAACGU-
GUCACGUTT-39) and microRNA inhibitor negative control
(NC): (59-CAGUACUUUUGUGUAGUACAA-39) were chemi-
cally synthesized by GenePharma (Shanghai, China).
Cell Culture
Human breast cancer cell lines BT-474, T-47D and MDA-MB-
231 were cultured in RPMI-1640 medium (Gibco, Shanghai,
China) with 10% FBS (Gibco, Gaithersburg, USA), 1% NEAA
(Hyclone, Logan, Utah, USA), 1% sodium pyruvate (Hyclone) and
1% penicillin-streptomycin (Gibco, Gaithersburg, USA). Human
breast cancer cell lines MCF-7 and SK-BR-3 were cultured in
MEM medium (Gibco, Shanghai, China) and Mccoy’s medium
(Gibco, Gaithersburg, USA) with 10% FBS, 1% NEAA, 1%
Figure 7. MiR-137 influences cell proliferation in SK-BR-3 cells partly through ERRa-CCNE1 axis. A. re-expression of ERRa (without 39-
UTR) in SK-BR-3 cells transfected with miR-137 reversed the decrease of CCNE1 expression induced by miR-137. qRT-PCR analysis for ERRa and CCNE1
mRNA level and western blot analysis for ERRa and CylinE1 protein level in SK-BR-3 cells 48 hr after transfection. CCNE1 or ERRa mRNA expression
was normalized to b-actin mRNA expression. The relative level of CCNE1 or ERRa determined using the 2-
ggCT method. Data are representative of
three independent experiments performed in duplicate. Error bars: SD; **: P,0.01; ***: P,0.0001. B. re-expression of ERRa (without 39-UTR) in SK-BR-3
cells transfected with miR-137 partly rescued the arrested cell cycle progression. Cell cycle analysis using propidium iodide staining and flow
cytometry was performed in SK-BR-3 cells transfected with indicated RNA oligonucleotides (50 nM) and plasmids (300 ng) for three days. The
percentage of cells in each cell cycle phases was quantified. Error bars: SD; *: p,0.05; ***: P,0.0001. C. re-expression of ERRa (without 39-UTR) in SK-
BR-3 cells transfected with miR-137 partly rescued the impaired proliferation capacity. SK-BR-3 cells were transfected with indicated RNA
oligonucleotides (50 nM) and plasmids (30ng) and seeded in 96-well plates. Plates were harvested at 1, 3, 5, 7 days after seeding. Cell numbers were
determined by CCK-8 assay.
doi:10.1371/journal.pone.0039102.g007
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human breast epithelial cell line MCF-10A was cultured in
DMEM/F-12 (Hyclone) with 5% horse serum (MinHai Bio-
engineering, Lanzhou, China), 10 ug/ml insulin (Sigma-Aldrich,
Saint Louis, MO, USA), 20 ng/ml EGF (Sigma-Aldrich), 100ng/
ml cholera toxin (Calbiochem, Darmstadt, Germany), 0.5 ug/ml
hydrocortisone (Sigma-Aldrich) and 1% penicillin-streptomycin.
The human liver hepatocellular carcinoma cell line HepG2 was
cultured in DMEM medium (Gibco, Shanghai, China) with 10%
FBS, 1% NEAA, 1% sodium pyruvate and 1% penicillin-
streptomycin. All cultured cell lines were purchased from ATCC.
Luciferase Reporter Plasmids Construction
To construct the reporter plasmids contain consensus or
mismatch miR-137 target site, oligonucleotide pairs that contain
the desired miR-137 target region and restriction enzymes sites
(Nhe I and Sal II) were annealed and ligated into the Firefly-
Renilla dual reporter vector-pmirGLO Vector (Promega, Madi-
son, WI, USA). For construction of reporter plasmids with wide
type or mutant ESRRA3’UTR, total RNA from SK-BR-3 cells
was reverse transcribed to the first strand of cDNA by SuperScript
III kit (Invitrogen, Carisbad, CA, USA) with the primer oligo
(dT)18 (Takara, Dalian, China). The 39 UTR of the human ERRa
gene (NM_004451) was amplified by PCR with the cDNA of SK-
BR-3 cells as template. Purified PCR products were inserted
downstream of the firefly luciferase gene in the Firefly-Renilla dual
reporter vector- pmirGLO-vector after digested by Nhe I and Sal
II (Takara). The construct was designated as WT 39UTR. The
deletion mutated 39UTR were amplified by PCR with WT3’UTR
as the template using the site-directed mutagenesis kit (Takara),
inserted into the same reporter vector and named mutant A,
mutant B and mutant C, respectively. The sequences of primers
used for luciferase reporter plasmids construction were shown in
Table 1.
Transfection
RNA oligonucleotides were transfected into cells using Lipofec-
tamine RNAiMAX (Invitrogen) according to the manufacture’s
Figure 8. MiR-137 influences the migratory capacity of MDA-MB-231 cells partly through ERRa-WNT11 signaling pathway. A. re-
expression of ERRa (without 39-UTR) in MDA-MB-231 cells restored the impaired migratory capacity induced by miR-137. MDA-MB-231 cells were co-
transfected with indicated RNA oligonucleotides (50 nM) and plasmids (1 mg), and serum starved for 12 hr, followed by assessment of cell invasion
and viability. Error bars: SD; *: p,0.05; **: P,0.01; ***: P,0.0001. B. re-expression of ERRa (without 39-UTR) in MDA-MB-231 cells reversed the
decrease of WNT11 expression induced by miR-137. MDA-MB-231 cells were co-transfected with indicated RNA oligonucleotides (50 nM) and
plasmids (1 mg). 48 hr after transfection, protein and mRNA levels of WNT11 and ERRa were assayed using western bolt and qRT-PCR respectively.
WNT11 or ERRa mRNA expression was normalized to b-actin mRNA expression. The relative level of WNT11 or ERRa determined using the 2-
ggCT
method. Data are representative of three independent experiments performed in duplicate. Error bars: SD; **: P,0.01; ***: P,0.0001.
doi:10.1371/journal.pone.0039102.g008
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for rescue experiment are co-transfected into cells using instant-
FECT according to the manufacture’s protocol of reverse trans-
fection.
Luciferase Assay
Cells were seeded in 24-well plate with regular growth medium
without antibiotics 1 day before transfection and transiently co-
transfected with the reporter plasmid (150 ng/well) and miR-137
mimics or its NC oligos at the concentration of 20 nM/well using
lipofectamime 2000 (Invitrogen). Twenty-four hours after trans-
fection, cell lysates were collected and luciferase activities were
measured by a Dual-Luciferase Reporter System (Promega) using
TD 20/20 luminometer (Promega) following the manufacturer’s
protocol. The luminescence intensity of Firefly luciferase was
normalized to that of Renilla luciferase.
ERRa Inverse Agonist XCT-790 Treatment
Cells were seeded in 6-well plate. The following day, change the
medium with fresh medium with DMSO (Sigma-Aldrich) or
XCT-790 (Sigma-Aldrich) at a final concentration of 2.5 mM,
5 mM, 10 mM respectively. Cells were harvested 48 hr after
treatment for RNA or protein extraction.
Endogenous miR-137 Expression Assay by Real-time RT-
PCR
Total RNAs, including total miRNAs, were isolated from
cultured cell lines using Qiazol and miRNeasy Mini kit (QIAGEN,
Maryland, USA), according to the manufacture’s instructions. The
RT reactions were performed according to TaqManH small RNA
Assay protocol by using commercial small RNA primers of has-
miR-137 or RNU6B in a 15 ml volume with 10 ng total RNA.
Real-time PCR was performed using ABI 7900 HT system in a 96
well plate format. All reagents were purchased from Applied
Biosystems, Inc. (Foster City, CA). The expression levels of mature
miR-137 were normalized relative to RNU6B-small nuclear RNA,
the fold change in miR-137 expression was obtained using
the2-
ggCT method.
mRNA Expression Assay by Quantitative PCR Analysis
Total RNA was extracted using Trizol (Invitrogen) and reverse-
transcribed into cDNA with reverse transcriptase M-MLV
(Invitrogen) following the manufacturer’s manual. Quantitative-
Real-time PCR was performed using IQ
TM SYBR Green
Supermix (Bio-Rad, Hercules, CA, USA) on the iQ-5 Real-time
PCR Detection System (Bio-Rad). Expression level of ERRa,
CCNE1 and WNT11 mRNA were normalized to b-actin mRNA.
The relative level of mRNA was determined using the 2-
ggCT
method. The sequences of primers used for quantitative PCR
analysis were shown in Table 1.
Western Blot
Total cell lysates were prepared using protein lysis buffer
(150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 7.4), 1 mM
EDTA) containing a cocktail of protease inhibitor (Roche,
Shanghai, China). Equal amounts of protein sample (40–50 mg)
was separated by 8% SDS-PAGE and transferred to PVDF
membrane (Millipore, Bedford, MA, USA) using the Bio-Rad
semi-dry transfer system. After 1 hr blocking in 16Tris-buffered
saline with 5% non-fat milk at 37uC, the membrane was
immunoblotted overnight at 4uC with primary antibody. The
antibodies used were as follows: anti-ERRa rabbit polyclonal
antibody (1:500, Millipore, cat. #07-662), anti-CyclinE1 rabbit
monoclonal antibody (1:800, Millipore cat. #04-222), anti-
WNT11 rabbit polyclonal antibody (1:600, abcam, cat.a-
b31962),anti-b-actin mouse monoclonal antibody (1:500, Santa
Cruz, California, USA cat. sc-47778). Horseradish peroxidase
labeled goat anti-mouse or goat anti-rabbit secondary antibody
(Zsbio, Shanghai, China) was incubated with the membrane at
a concentration of 1:30000 for 1 hr at 37uC. After washing with
16TBST, signals were detected by incubating membrane with
ECL reagent from Thermo (Rockford, IL, USA) and exposing it to
an x-ray film and developed.
Cell Proliferation Assay
To measure cell proliferation, cells were seeded at a density of
2000-7000 cells per well into 96-well plates at Day0 (initiate from
small RNAs or plasmids transfection). The plates were harvested
for Cell Counting Kit-8 (Dojindo Laboratories Kumamoto, Japan)
measurement at indicated time point. The OD values at 450 nM
were measured using the multiskan spectrum (Thermo) with
SkanIt software 2.2.
Cell Cycle Assay
Cells were trypsinized 72 h after transfection. Cell pellets
harvested by centrifugation were washed for twice with ice-cold
PBS and fixed with ice-cold 70% ethanol for 48 hr at 4uC.
Staining for DNA content was performed with 50 mg/ml
propidium iodide (Sigma-Aldrich) and 1 mg/ml RNase A
(Sigma-Aldrich) for 30 min. Cell cycle analysis was performed
with a million cells in each group on FACSCalibur
TM (BD
Bioscience) with Muticycle for Windows software (Beckman
coulter).
BrdU Incorporation Assay
SK-BR-3 cells were seeded at a density of 2000 cells per well
into 96-well plate at Day0 (initiate from miR-137 mimics and
miR-137 inhibitors transfection). At day3, the cells were harvested
Table 1. Primers used for PCR.
Primer name Sequence
WT 39UTR Forward 59- AGAGCTAGCGGCAAGGGGTGGGACTG-39
WT 39UTR Reverse 59- CGCGTCGACGAGCTCGGTATTATATAT-39
Mutant A Forward 59-CTCCAAGCAGACTCCAGCCCCTGGAC-39
Mutant A Reverse 59-TCAAGGGGGGACACTAATGCCCAATG-39
Mutant B Forward 59-CACTATATTTATTTTTGGGTTTGGCCAGGG-39
Mutant B Reverse 59-CTGCAGGGCATAGAGGCAGTGCTCTC-39
Q-ESRRA Forward 59-GGCCCTTGCCAATTCAGA-39
Q-ESRRA Reverse 59-GGCCTCGTGCAGAGCTTCT-39
Q-CCNE1 Forward 59-CTGGACAAAGCCCGAGCAAAG-39
Q-CCNE1 Reverse 59-CCTCCGCTGCAACAGACAGAA-39
Q-WNT11 Forward 59-GCTTGTGCTTTGCCTTCACTTGGA-39
Q-WNT11 Reverse 59-TGGCCCTGAAAGGTCAAGTCTGTA-39
Q-ACO2 Forward 59-GATCCACGAGACCAACCTGAAGAA-39
Q-ACO2 Reverse 59-CCTTCATTCTGTTGAGGGCACTGC-39
Q-b-actin Forward 59-CACCAACTGGGACGACAT-39
Q-b-actin Reverse 59-GCACAGCCTGGATAGCAAC-3
The recognition sites of restriction endonuclease are underlined.
doi:10.1371/journal.pone.0039102.t001
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following the manufacturer’s instructions.
Transwell Assay
Forty eight hours after transfection, 2.5610
4 MDA-MB-231
cells were suspended in 500 mL serum free culture medium and
plated in duplicate in the top chamber with matrigel-coated
membrane (24-well insert; pore size 8 mm; Becton Dickinson). The
cells migrated toward culture medium with 10% FBS for 16 hours,
after which the cells did not invade were removed. Cells on the
lower surface of the membrane were stained in 5% crystal violet in
20% methanol and counted under microscope. Cell viability
assays were performed in parallel with the invasion assay using the
Cell Counting Kit-8. Cells (2.5610
4 cells in 100 mL medium) were
seeded in quadruplicate on a 96-well plate for 16 hours followed
by the addition of CCK8 for 1 hour. The OD values at 450 nM
were measured using the multiskan spectrum with SkanIt software
2.2 (Thermo), and the relative cell viability was quantified.
Statistical Analysis
Results are displayed as the mean6SD from duplicate or
triplicate samples for each group. Significant differences were
established by either the Student’s t-test or one-way ANOVA,
according to the number of groups compared, using the computer
program GraphPad Prism (GraphPad Software Inc V4.03, San
Diego, CA, USA). When significant variations were found by one-
way ANOVA, the Tukey-Kramer multiple comparisons post-test
was performed.
Supporting Information
Figure S1 The HepG2 cells express relatively lower
level of endogenous ERRa. Western-blot analysis for ERRa
protein level in three breast cancer cell lines (BT-474, MCF-7 and
SK-BR-3) and human liver hepatocellular carcinoma cell line
HepG2. b-actin was used as the loading control.
(TIF)
Figure S2 Sliencing of ERRa by si-ERRa or miR-137
mimics in MCF-7, BT-474 and MDA-MB-231 cell line.
Western blot analysis for ERRa protein level in MCF-7 (A), BT-
474 (B) and MDA-MB-231 (C) cells 48 hr after transfection regent
treatment (mock) or transfection with NC oligos, si-ERRa or miR-
137 mimics. b-actin was used as the loading control.
(TIF)
Figure S3 The effect of miR-137 treatment on ACO2 and
ERBB2 expression. A. qRT-PCR analysis for ACO2 level in
SK-BR-3 cells 48 hr after transfection with NC-oligos, si-ERRa or
miR-137 mimics. B. qRT-PCR analysis for ERBB2 level in SK-
BR-3 cells 48 hr after transfection with NC-oligos, si-ERRa or
miR-137 mimics. ACO2 and ERBB2 expression was normalized
to b-actin mRNA expression. The relative expression level of was
determined using the 2-
ggCT method. Data are representative of
three independent experiments performed in triplicate. Error bars:
SD; *: p,0.05; **: p,0.01.
(TIF)
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